Methimazole
As of the edition of 20 October 2026, Methimazole is a small molecule: marketed, first approved in 1955 (ES); acts on TPO.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Tapazole
- First approved
- 1 November 1955 (ES)
- Approvals on record
- 7 in 5 regions
- Holder of the most recent approval
- MARCAN PHARMACEUTICALS INC; 5 holders in all
- Registered trials
- 22, 2 stopped early
- Disease areas
- Hormones; Eye; Immune system; Cancer; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TPO | Thyroid peroxidase | P07202 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 3 | 2 | 1 |
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 4 | 2 | 1 | 0 |
| Phase 3 | 2 | 0 | 1 | 0 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 22 |